Aetiology of fatal viral hepatitis in Melbourne: A retrospective study

McNeil, Mara; Hoy, Jennifer; Mj, Richards; Ni, Lehmann; Dimitrikakis, M; Id, Gust; Cr, Lucas

doi:10.5694/j.1326-5377.1984.tb113175.x

Cited by 49 publications

(13 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This method provides an opportunity to obtain the collective judgement of those most familiar with the clinical and epidemiologic literature, and is required because studies of hepatitis A outcomes are often limited or conflicting. The first survey requested age-specific estimates of hepatitis A outcomes, with each item preceded by a summary of literature describing risks of hospitalization, 1,2,4,5,7,12 fulminant disease, [13][14][15] liver transplant, 16 and mortality. 1,2,17,18 Panelists also described treatment patterns for a typical patient with fulminant disease, using a structure similar to the case-series study.…”

Section: Methodsmentioning

confidence: 99%

The cost of hepatitis A infections in American adolescents and adults in 1997

Berge¹,

Drennan²,

Jacobs³

et al. 2000

Hepatology

119

View full text Add to dashboard Cite

The incidence of hepatitis A has declined in the United States for several decades, leading to an increased number of susceptible adolescents and adults. Because clinical severity increases with age, hepatitis A infections in older individuals cause greater morbidity, mortality, and treatment costs. Because the economic burden of hepatitis A has not been well described, we estimated its costs, from the societal perspective, for patients infected at distinct ages. A case-series study described treatment patterns, work loss, and symptom duration. Disease outcomes were estimated by an expert panel. Economic losses were calculated by applying normative data reflecting treatment charges, employee compensation, and the value of housekeeping services. In the case-series study, mean treatment charges were $740 for nonhospitalized patients versus $6,914 for hospitalized patients (P F .001). Symptom duration (67.8 vs.

show abstract

Section: Methodsmentioning

confidence: 99%

The cost of hepatitis A infections in American adolescents and adults in 1997

Berge¹,

Drennan²,

Jacobs³

et al. 2000

Hepatology

119

View full text Add to dashboard Cite

show abstract

“…38). 9 expert reviews in molecular medicine prothrombinase, which activates the coagulation pathway by cleaving prothrombin to thrombin. Thrombin then cleaves fibrinogen to insoluble fibrin, which contributes to intravascular thrombosis.…”

Section: Mhv-3-induced Fhf Modelmentioning

confidence: 99%

Fulminant viral hepatitis: molecular and cellular basis, and clinical implications

Liu

Chan

McGilvray

et al. 2001

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

show abstract

“…We convened a panel of 6 hepatitis experts and conducted 3 sequential surveys using the Delphi method. 16 The first survey was accompanied by literature summaries and requested the following: age-specific estimates of the probability of symptomatic infection, [17][18][19] hospitalization, 2,8,11,12 acute liver failure, [20][21][22] liver transplantation, 23 and mortality 2,8,24,25 ; estimates of long-term vaccine efficacy following 1 or 2 doses [4][5][6][7] ; and profiles describing the number of physician visits, hospital days, imaging studies, laboratory tests, and drugs that would be ordered for a typical patient treated as an outpatient or inpatient. The second survey included a summary of first-round estimates and required panelists to reconsider their initial responses in light of their peers' estimates.…”

Section: Expert Panel Surveymentioning

confidence: 99%